{"id":"control-vaccine","safety":{"commonSideEffects":[{"rate":"5–10","effect":"Injection site pain or swelling"},{"rate":"5–10","effect":"Fatigue"},{"rate":"3–8","effect":"Myalgia"},{"rate":"3–8","effect":"Headache"},{"rate":"1–5","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) SARS-CoV-2 virus particles that trigger both humoral (antibody) and cell-mediated immune responses without causing active infection. This approach allows the immune system to recognize and mount a protective response against the virus upon natural exposure. Sinovac's CoronaVac uses this traditional inactivated virus platform, which has a long safety track record in other vaccines.","oneSentence":"Control Vaccine is an inactivated whole-virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:05.912Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 caused by SARS-CoV-2"}]},"trialDetails":[{"nctId":"NCT07495202","phase":"PHASE1","title":"A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JunTop Biosciences Co., LTD","startDate":"2026-03-30","conditions":"Health Volunteer","enrollment":180},{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT07498075","phase":"NA","title":"A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-04-01","conditions":"HPV, HPV Vaccine","enrollment":3340},{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT02639299","phase":"","title":"Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-08","conditions":"Malaria","enrollment":1500},{"nctId":"NCT00001539","phase":"","title":"A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1996-06-13","conditions":"Lyme Disease","enrollment":700},{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT04381689","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-23","conditions":"Healthy","enrollment":245},{"nctId":"NCT07492706","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2026-04-01","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":120},{"nctId":"NCT07003984","phase":"PHASE3","title":"A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.","status":"RECRUITING","sponsor":"Bavarian Nordic","startDate":"2025-06-05","conditions":"Chikungunya Virus","enrollment":720},{"nctId":"NCT07256912","phase":"PHASE4","title":"A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia","status":"NOT_YET_RECRUITING","sponsor":"International Agency for Research on Cancer","startDate":"2026-04-01","conditions":"Vaccine Effectiveness, HPV Vaccination, Single Dose","enrollment":1266},{"nctId":"NCT05380388","phase":"PHASE2","title":"A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2027-01-01","conditions":"Plasmodium Vivax Infection, Malaria Vaccine","enrollment":36},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT06862453","phase":"PHASE1","title":"Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults","status":"NOT_YET_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2026-03","conditions":"Malaria Falciparum","enrollment":58},{"nctId":"NCT07488962","phase":"NA","title":"Building Cognitive Resilience to Vaccine Misinformation Using AI: Evidence From a Randomised Trial","status":"NOT_YET_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2026-03","conditions":"Healthy","enrollment":1000},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT07128615","phase":"PHASE1, PHASE2","title":"A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-04","conditions":"Influenza A","enrollment":405},{"nctId":"NCT06738355","phase":"NA","title":"PREVENT Pilot HPV - Related Cancers Trial","status":"COMPLETED","sponsor":"University of Utah","startDate":"2025-05-20","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":335},{"nctId":"NCT07485283","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2026-03","conditions":"Cardiovascular Disease, Dementia","enrollment":162000},{"nctId":"NCT04350138","phase":"PHASE2","title":"Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-29","conditions":"Gonococcal Infection","enrollment":2606},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT06950645","phase":"PHASE1","title":"The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-03-27","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT04649021","phase":"PHASE2","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":960},{"nctId":"NCT07300267","phase":"PHASE1","title":"A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-13","conditions":"Pneumococcal Infection","enrollment":210},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT05037279","phase":"PHASE3","title":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","status":"RECRUITING","sponsor":"Verity Pharmaceuticals Inc.","startDate":"2024-04-24","conditions":"Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence","enrollment":540},{"nctId":"NCT05766904","phase":"PHASE3","title":"Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-04","conditions":"Gonorrhea, Sexually Transmitted Infection","enrollment":150},{"nctId":"NCT07013487","phase":"PHASE3","title":"A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-11","conditions":"Healthy","enrollment":12000},{"nctId":"NCT06669208","phase":"PHASE1","title":"Trial of an Inactivated Chikungunya Virus Vaccine","status":"COMPLETED","sponsor":"Najit Technologies, Inc.","startDate":"2024-11-04","conditions":"Chikungunya Fever, Chikungunya Virus, Chikungunya","enrollment":48},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT06719219","phase":"PHASE1","title":"A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2025-01-07","conditions":"Staphylococcus (S.) Aureus Infection","enrollment":129},{"nctId":"NCT07481604","phase":"PHASE2","title":"Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CHA Vaccine Institute Co., Ltd.","startDate":"2026-04","conditions":"Herpes Zoster","enrollment":135},{"nctId":"NCT05765773","phase":"PHASE2","title":"An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2021-07-01","conditions":"Corona Virus Infection, Vaccine, COVID-19","enrollment":200},{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT04579588","phase":"","title":"Understanding Immunity to the Flu Vaccine in COVID-19 Patients","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-10-29","conditions":"Corona Virus Infection, Flu Vaccine, Immunity","enrollment":230},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT05500482","phase":"PHASE4","title":"Vellore Typhoid Vaccine Impact Trial","status":"COMPLETED","sponsor":"Christian Medical College, Vellore, India","startDate":"2023-05-01","conditions":"Typhoid Fever","enrollment":72400},{"nctId":"NCT05705440","phase":"PHASE3","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-02-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":3855},{"nctId":"NCT07467707","phase":"PHASE3","title":"An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults","status":"NOT_YET_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2026-05","conditions":"Chikungunya Virus","enrollment":6144},{"nctId":"NCT06692907","phase":"PHASE2","title":"Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-31","conditions":"Escherichia Infection","enrollment":72},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT05528952","phase":"PHASE2","title":"Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-09-27","conditions":"Hepatocellular Carcinoma","enrollment":105},{"nctId":"NCT07473986","phase":"","title":"REAl LIfe\" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-07-08","conditions":"SARS-CoV-2 Omicron Variants","enrollment":88},{"nctId":"NCT05683457","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-04-05","conditions":"Cytomegalovirus Infection","enrollment":224},{"nctId":"NCT07284654","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2025-12-01","conditions":"Pneumococcal Vaccines","enrollment":4000},{"nctId":"NCT06926062","phase":"NA","title":"Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":1900},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT06688058","phase":"PHASE1","title":"A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Healthy","enrollment":72},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT06134648","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-11-01","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus","enrollment":646},{"nctId":"NCT06181292","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-11-15","conditions":"SARS-CoV2 Infection","enrollment":913},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":"HIV I Infection, Tuberculosis","enrollment":276},{"nctId":"NCT03172975","phase":"PHASE2","title":"Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2018-03-01","conditions":"Hookworm Infections","enrollment":39},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT05142553","phase":"PHASE2","title":"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2021-11-16","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":887},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT05446740","phase":"PHASE1","title":"A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-09","conditions":"Influenza, Human","enrollment":324},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT07459946","phase":"NA","title":"Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence","status":"NOT_YET_RECRUITING","sponsor":"Jiazhen Yin","startDate":"2026-03-12","conditions":"Diabetic Nephropathy Type 2, Chronic Renal Failure/ Kidney Disease","enrollment":198},{"nctId":"NCT06387511","phase":"NA","title":"Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months","status":"COMPLETED","sponsor":"Alliance for International Medical Action","startDate":"2024-05-07","conditions":"Immunization Coverage, Vaccination, Nutrition","enrollment":3814},{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT06098690","phase":"NA","title":"Culturally Tailored HPV Psychoeducational Multimedia Intervention","status":"RECRUITING","sponsor":"University of Texas, El Paso","startDate":"2024-05-02","conditions":"Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention","enrollment":63},{"nctId":"NCT06050356","phase":"PHASE1","title":"First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","status":"ACTIVE_NOT_RECRUITING","sponsor":"Statens Serum Institut","startDate":"2024-03-14","conditions":"Healthy","enrollment":140},{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT06251024","phase":"PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-02","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers","enrollment":4541},{"nctId":"NCT07220109","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":750},{"nctId":"NCT06805487","phase":"PHASE1","title":"Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-24","conditions":"Zika Virus","enrollment":27},{"nctId":"NCT05580458","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-13","conditions":"Herpes Zoster","enrollment":225},{"nctId":"NCT07457060","phase":"PHASE4","title":"Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-11-27","conditions":"Poliomyelitis","enrollment":480},{"nctId":"NCT07217145","phase":"NA","title":"PREVENT HPV -Related Cancers Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2025-10-09","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":1455},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT07454915","phase":"PHASE2","title":"PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia","status":"NOT_YET_RECRUITING","sponsor":"PapiVax Biotech, Inc.","startDate":"2026-03-01","conditions":"Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16","enrollment":138},{"nctId":"NCT07092865","phase":"PHASE2","title":"A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-06","conditions":"Respiratory Syncytial Virus Infections","enrollment":184},{"nctId":"NCT07455305","phase":"NA","title":"The Effect of Simultaneous Versus Sequential Intramuscular Vaccine Injections on Pain Levels in Infants","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2021-09-01","conditions":"Injection Pain Prevention, Injection Pain","enrollment":110},{"nctId":"NCT06272812","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-02-19","conditions":"Tuberculosis (TB)","enrollment":5500},{"nctId":"NCT06973772","phase":"PHASE3","title":"Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.","status":"NOT_YET_RECRUITING","sponsor":"Butantan Institute","startDate":"2026-03-31","conditions":"Dengue, Chikungunya","enrollment":900},{"nctId":"NCT07450703","phase":"NA","title":"The Effect of the Health Belief Model-Based Education Given to Mothers of Children Aged 9-15 on HPV Knowledge Level and Child Vaccination","status":"NOT_YET_RECRUITING","sponsor":"University of Gaziantep","startDate":"2026-04-01","conditions":"Cancer , Healthy, HPV - Anogenital Human Papilloma Virus Infection, Health Belief Model","enrollment":100},{"nctId":"NCT07164144","phase":"NA","title":"SAVE: School Ambassadors for Vaccine Education","status":"ENROLLING_BY_INVITATION","sponsor":"University of Rochester","startDate":"2026-04-01","conditions":"Influenza Vaccination","enrollment":6000},{"nctId":"NCT04335890","phase":"PHASE1","title":"IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma","status":"COMPLETED","sponsor":"Hasumi International Research Foundation","startDate":"2020-09-24","conditions":"Melanoma, Uveal Metastatic","enrollment":17},{"nctId":"NCT07252791","phase":"PHASE4","title":"Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-16","conditions":"Autoimmune Rheumatologic Disease","enrollment":114},{"nctId":"NCT07379580","phase":"PHASE2","title":"A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-20","conditions":"Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection","enrollment":310},{"nctId":"NCT06190509","phase":"PHASE1, PHASE2","title":"Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"LimmaTech Biologics AG","startDate":"2023-12-06","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":251},{"nctId":"NCT06754384","phase":"PHASE1, PHASE2","title":"Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-01-15","conditions":"Hand, Foot, and Mouth Disease (HFMD), Herpangina","enrollment":552},{"nctId":"NCT06036602","phase":"PHASE2","title":"Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2024-07-15","conditions":"Ebola Sudan Virus Disease","enrollment":125},{"nctId":"NCT05854381","phase":"PHASE1","title":"To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-09-19","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT07087912","phase":"PHASE4","title":"Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-10","conditions":"Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE)","enrollment":477},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT07445815","phase":"PHASE2","title":"A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody","status":"NOT_YET_RECRUITING","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2026-01-31","conditions":"Rabies (Healthy Volunteers)","enrollment":200},{"nctId":"NCT07447245","phase":"NA","title":"Parent Education About Human Papillomavirus (HPV)","status":"RECRUITING","sponsor":"KTO Karatay University","startDate":"2026-02-15","conditions":"HPV (Human Papillomavirus)-Associated","enrollment":52},{"nctId":"NCT04701151","phase":"PHASE4","title":"NORTH-REG Dwell-Time Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2021-02-03","conditions":"Side Effect of Drug","enrollment":314},{"nctId":"NCT07445763","phase":"","title":"TARSILA Real-World Evidence Study","status":"NOT_YET_RECRUITING","sponsor":"Inova Medical","startDate":"2026-04-30","conditions":"Respiratory Syncytial Virus (RSV), Maternal Immunization, Acute Respiratory Illness (ARI)","enrollment":5000},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT06975878","phase":"PHASE3","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":1092},{"nctId":"NCT05089630","phase":"PHASE1, PHASE2","title":"A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-14","conditions":"Cytomegalovirus Infections","enrollment":339},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT07443709","phase":"PHASE2","title":"Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Oriol Manuel","startDate":"2026-04","conditions":"Zoster; Herpes","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":461,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enterovirus Type 71 Vaccine, Inactivated（Human Diploid Cell）","Meningococcal C conjugate vaccine","Varicella vaccine","Locally available Meningococcal conjugate vaccine"],"phase":"marketed","status":"active","brandName":"Control Vaccine","genericName":"Control Vaccine","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Control Vaccine is an inactivated whole-virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2. Used for Prevention of COVID-19 caused by SARS-CoV-2.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}